Nuclear Medicine Market is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period

June 17, 2022

The Global Nuclear Medicine Market accounted for US$ 4.26 billion and is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period. Nuclear medicine may be a medicine involving the appliance of radioactive substances within the diagnosis and treatment of disease. Medicine imaging, during a sense, is “radiology done inside out” or “endoradiology” because it records radiation emitting from within the body instead of radiation that’s generated by external sources like X-rays. Additionally, medicine scans differ from radiology, because the emphasis isn’t on imaging anatomy, but on the function. For such reason, it’s called a physiological imaging modality. Single photon emission computerized tomography (SPECT) and positron emission tomography (PET) scans are the 2 commonest imaging modalities in medicine.

Analyst View:

Nuclear medicine shows a huge potential in treating cardiac and cancer diseases. Several factors are poised to augment the demand for nuclear medicine, but none bigger than the growing prevalence of cancer and cardiac disorders. Advances in radiotracers, the advent of alpha radioimmunotherapy (Rit)-based targeted cancer treatments, and investments via public and private partnerships to revolutionize diagnostic measures are some of the other factors expected to drive the demand for the target market shortly.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Nuclear Medicine Market, By Diagnostics (Single Photon Emission, Computed Tomography (SPECT), and Positron Emission Tomography (PET)), By Therapeutics (Alpha Emitters, Beta Emitters, and Brachytherapy), By Applications (Cardiology, Neurology, Oncology, and Other Applications), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2030”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Nuclear-Medicine-Market-By-3827#

The report ” Global Nuclear Medicine Market, By Diagnostics (Single Photon Emission, Computed Tomography (SPECT), and Positron Emission Tomography (PET)), By Therapeutics (Alpha Emitters, Beta Emitters, and Brachytherapy), By Applications (Cardiology, Neurology, Oncology, and Other Applications), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2030”

Key Highlights:

In 2021, Penn Medicine’s clinical, operational, and research and clinical capabilities, the health system is launching the Center for Applied Health Informatics to better facilitate and coordinate health data projects across the health system and grow its leadership in health informatics globally.
In 2021, Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation).
Key Market Insights from the report:

The Global Nuclear Medicine Market accounted for US$ 4.26 billion and is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period. The nuclear medicine market is segmented by diagnostics, by therapeutics, by applications, and by regions.

On the basis of Diagnostics, the Global Nuclear Medicine Market is segmented into Single Photon Emission, Computed Tomography (SPECT), and Positron Emission Tomography (PET).
On the basis of Therapeutics, the target market is segmented into Alpha Emitters, Beta Emitters, and Brachytherapy.
Based on Applications, the global market is classified into Cardiology, Neurology, Oncology, and Other Applications.
Based on region the Global Nuclear Medicine Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in North America region is seen to have a matured growth since this market correlates with the increasing growth rate of cancer.
Competitive Landscape:

The key players operating the global nuclear medicine market involves Eckert & Ziegler Group, Mallinckrodt Pharmaceuticals, GE Healthcare; Jubilant Life Sciences; Bracco Imaging S.p.A, Nordion, Inc., The Institute of Radioelements, Australian Nuclear Science & Technology Organization (ANSTO), NTP Radioisotopes SOC Ltd., and Eczacibasi-Monroe.

Other Topics: https://androidfun.fr/applications-et-perspectives-regionales-au-cours-de-la-periode-previsionnelle-2020-2030-marche-du-microbiome-humain/
https://androidfun.fr/marche-de-la-membrane-amniotique-dernieres-tendances-cles-et-analyse-des-opportunites-2/
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Article Categories:
Business

Leave a Comment

Your email address will not be published.